Hugel
Financials
Valuation Metrics
Hugel's Market Cap is ₩2.1T. At end of 2025 it was ₩2.9T. Ranked #191 of 2,414 in KR market (top 8%), #32 of 1,633 on KOSDAQ (top 2%), #15 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.12T KRW | KR#191/2,414 Sec#15/231 |
| Revenue | 479.57B KRW | KR#634/2,414 Sec#33/231 |
| Net Income | 163.22B KRW | KR#175/2,414 Sec#10/231 |
| Total Assets | 1.19T KRW | KR#434/2,414 Sec#23/231 |
| Net Assets | 1.09T KRW | KR#278/2,414 Sec#15/231 |
| Employees | 609 | KR#412/2,414 Sec#35/231 |
| Value | ||
| P/E | 12.99x | KR#1,005/2,414 Sec#56/231 |
| P/B | 1.95x | KR#1,948/2,414 Sec#147/231 |
| PEG | 1.40x | KR#777/2,414 Sec#50/231 |
| P/S | 4.42x | KR#2,123/2,414 Sec#139/231 |
| EV/EBITDA | 9.03x | KR#584/2,414 Sec#26/231 |
| FCF Yield | 6.45% | KR#792/2,414 Sec#38/231 |
| Profitability | ||
| ROE | 15.00% | KR#324/2,414 Sec#21/231 |
| ROA | 13.69% | KR#141/2,414 Sec#11/231 |
| Op. Margin | 43.56% | KR#17/2,414 Sec#5/231 |
| Revenue Growth | 18.88% | KR#580/2,414 Sec#54/231 |
| Earnings Growth | 9.30% | KR#761/2,414 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 9.57% | KR#129/2,414 Sec#28/231 |
| Total Debt | 26.30B KRW | KR#1,286/2,414 Sec#100/231 |
| FCF | 136.66B KRW | KR#146/2,414 Sec#6/231 |
| Cash | 259.56B KRW | KR#222/2,414 Sec#7/231 |
| Current Ratio | 7.55x | KR#158/2,414 Sec#34/231 |
| Net Debt/EBITDA | -1.12x | KR#359/2,414 Sec#18/231 |
| Performance | ||
| 1Y Return | -37.83% | KR#1,689/2,414 Sec#146/231 |
| 1M Return | -28.37% | KR#2,312/2,414 Sec#219/231 |
| From 52W High | -45.09% | KR#1,000/2,414 Sec#74/231 |
| 1Y MDD | -43.06% | KR#688/2,414 Sec#51/231 |
| Trading | ||
| Volume | 38,028 shares | KR#1,516/2,414 Sec#147/231 |
| Trading Value | 6.36B KRW | KR#332/2,414 Sec#26/231 |
| Foreign Own. | 58.53% | KR#21/2,414 Sec#1/231 |
| Per Share | ||
| EPS | 13,042 KRW | KR#84/2,414 Sec#6/231 |
| BPS | 86,924 KRW | KR#159/2,414 Sec#8/231 |
Company Info
Established in 2001, this global medical aesthetics company listed on KOSDAQ in 2015 and absorbed Hugel Pharma in 2018. Its core business involves the research, development, manufacturing, and sales of Type A botulinum toxin and hyaluronic acid fillers, including products like BOTULAX, The Chaeum, and Wellage. The company drives innovation through technologies such as artificial intelligence and robotics, providing comprehensive solutions for diverse aesthetic needs to enhance corporate value. Hugel was established in 2001 and is headquartered in Chuncheon-si, Gangwon Special Self-Governing Province.